{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:31:43Z","timestamp":1789129903292,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jpba.2026.117550","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T14:26:30Z","timestamp":1778423190000},"page":"117550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Identification, toxicity evaluation, and HPLC-based quality control method development of process-related impurities and degradation products of belumosudil mesylate"],"prefix":"10.1016","volume":"279","author":[{"given":"Yabo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangjian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117550_bib1","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1021\/acs.jmedchem.4c00750","article-title":"Development and evaluation of indole-based phospholipase D inhibitors for lung cancer immunotherapy","volume":"68","author":"Song","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2026.117550_bib2","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s40265-021-01593-z","article-title":"Belumosudil: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2026.117550_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1254\/fpj.24091","article-title":"Pharmacological characteristics and domestic clinical trial results of the selective ROCK2 inhibitor Belumosudil Mesylate (Rezurock\u00ae Tablets 200 mg)","volume":"160","author":"Yuuya","year":"2025","journal-title":"Folia Pharmacol. Jpn."},{"key":"10.1016\/j.jpba.2026.117550_bib4","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jpba.2026.117550_bib5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 Inhibition With Belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2026.117550_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jpba.2018.07.050","article-title":"Risk-based approach for method development in pharmaceutical quality control context: a critical review","volume":"161","author":"Deidda","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117550_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2026.117355","article-title":"Identification and characterization of trametinib degradation product employing Orbitrap LC-HRMS, and development of a robust, eco-friendly stability indicating method of analysis","volume":"272","author":"Jawarkar","year":"2026","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117550_bib8","unstructured":".International Conference Harmonization (ICH) harmonized tripartite guideline, Impurities in New Drug Substances Q3A (R2), October 25, 2006."},{"key":"10.1016\/j.jpba.2026.117550_bib9","unstructured":"Guidance for Industry: Q3B (R2) Impurities in New Drug Product, International Conference on Harmonisation, 2006."},{"key":"10.1016\/j.jpba.2026.117550_bib10","unstructured":"Guideline for Assessment and Control of DNA Reactive (mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, M7, ICH, 2014."},{"key":"10.1016\/j.jpba.2026.117550_bib11","unstructured":"International Council for Harmonisation (ICH) Guideline, Q2 (R2): Validation of Analytical Procedures, International Council for Harmonisation, Geneva, Switzerland, 2023."},{"key":"10.1016\/j.jpba.2026.117550_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116085","article-title":"Impurity assessment, development and validation of an RP-HPLC method for the determination of eleven potential impurities of eltrombopag precursor","volume":"243","author":"Demirhan","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117550_bib13","article-title":"Preparation of 4-[(1H-indazol-5-yl) amino] quinazolines as ROCK1 and\/or ROCK2 kinase inhibitors with improved pharmacokinetic properties","volume":"2006105081","author":"Stewart","year":"2006","journal-title":"WO"},{"key":"10.1016\/j.jpba.2026.117550_bib14","article-title":"Preparation of quinazoline derivatives as metabolic inhibitors","volume":"2012040499","author":"Enoch","year":"2012","journal-title":"WO"},{"key":"10.1016\/j.jpba.2026.117550_bib15","author":"Yan","year":"2017","journal-title":"Synth. Method SLx-2119"},{"key":"10.1016\/j.jpba.2026.117550_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.70161","article-title":"Identification and characterization of belumosudil degradation impurities using the LC\u2013MS\/MS method and its validation","volume":"39","author":"Koganti","year":"2025","journal-title":"Biomed. Chromatogr."},{"issue":"19","key":"10.1016\/j.jpba.2026.117550_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38369","article-title":"Comprehensive chromatographic analysis of Belumosudil and its degradation products: development, validation, and In silico toxicity assessment","volume":"10","author":"Ali","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jpba.2026.117550_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115614","article-title":"Characterization, quantification and a multi-computational in silico toxicity assessment of impurity (feruloyl methane) in synthetic curcumin using RP-HPLC-UV technique","volume":"235","author":"Nunavath","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117550_bib19","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpba.2026.117550_bib20","doi-asserted-by":"crossref","first-page":"W257","DOI":"10.1093\/nar\/gky318","article-title":"ProTox-II: a webserver for the prediction of toxicity of chemicals","volume":"46","author":"Banerjee","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpba.2026.117550_bib21","doi-asserted-by":"crossref","first-page":"16750","DOI":"10.1021\/acs.jmedchem.5c01618","article-title":"CLaSP: a contrastive learning-guided latent scoring platform for comprehensive drug-likeness evaluation","volume":"68","author":"Xinmin","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2026.117550_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116899","article-title":"Exploring the potential mechanisms of Jinglinzi powder in treating hepatocellular carcinoma based on LC-MS, network pharmacology, molecular docking, and experimental validation","volume":"263","author":"Liu","year":"2025","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526002189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526002189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:22:38Z","timestamp":1780528958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526002189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"alternative-id":["S0731708526002189"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117550","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification, toxicity evaluation, and HPLC-based quality control method development of process-related impurities and degradation products of belumosudil mesylate","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117550"}}